{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:56:06Z","timestamp":1762898166401},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1093\/fampra\/cmi096","type":"journal-article","created":{"date-parts":[[2005,12,7]],"date-time":"2005-12-07T03:13:18Z","timestamp":1133925198000},"page":"20-27","source":"Crossref","is-referenced-by-count":18,"title":["Pitfalls in blood pressure measurement in daily practice"],"prefix":"10.1093","volume":"23","author":[{"given":"ST","family":"Houweling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kleefstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HL","family":"Lutgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KH","family":"Groenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B Meyboom-de","family":"Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HJG","family":"Bilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"key\n\t\t\t\t20171012073151_B1","doi-asserted-by":"crossref","unstructured":"Campbell NR, Myers MG, McKay DW. Is usual measurement of blood pressure meaningful? Blood Press Monit1999; 4:71\u201376.","DOI":"10.1097\/00126097-199902000-00003"},{"key":"key\n\t\t\t\t20171012073151_B2","doi-asserted-by":"crossref","unstructured":"O'Brien E, Asmar R, Beilin L et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens2003; 21:821\u2013848.","DOI":"10.1097\/00004872-200305000-00001"},{"key":"key\n\t\t\t\t20171012073151_B3","doi-asserted-by":"crossref","unstructured":"Beevers G, Lip GY, O'Brien E. Blood pressure measurement. Part I. Sphygmomanometry: Factors common in all techniques. BMJ2001; 322:981\u2013985.","DOI":"10.1136\/bmj.322.7292.981"},{"key":"key\n\t\t\t\t20171012073151_B4","doi-asserted-by":"crossref","unstructured":"McVicker JT. Blood pressure measurement\u2014does anyone do it right?: An assessment of the reliability of equipment in use and the measurement techniques of clinicians. J Fam Plann Reprod Health Care2001; 27:163\u2013164.","DOI":"10.1783\/147118901101195407"},{"key":"key\n\t\t\t\t20171012073151_B5","unstructured":"McKay DW, Campbell NR, Parab LS, Chockalingam A, Fodor JG. Clinical assessment of blood pressure. J Hum Hypertens1990; 4:639\u2013645."},{"key":"key\n\t\t\t\t20171012073151_B6","doi-asserted-by":"crossref","unstructured":"Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003; 42:1206\u20131252.","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"key\n\t\t\t\t20171012073151_B7","doi-asserted-by":"crossref","unstructured":"Ramsay L, Williams B, Johnston G et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens1999; 13:569\u2013592.","DOI":"10.1038\/sj.jhh.1000917"},{"key":"key\n\t\t\t\t20171012073151_B8","unstructured":"Walma EP, Thomas S, Prins A, Grundmeyer HGLM, Van der Laan JR, Wiersma TJ. NHG-Standaard Hypertensie (derde herziening). (transl: NHG [Dutch General practitioners Society] guidelines for hypertension [3rd revision]). Huisarts Wet2003; 46:434\u2013448."},{"key":"key\n\t\t\t\t20171012073151_B9","doi-asserted-by":"crossref","unstructured":"Perloff D, Grim C, Flack J et al. Human blood pressure determination by sphygmomanometry. Circulation1993; 88:2460\u20132470.","DOI":"10.1161\/01.CIR.88.5.2460"},{"key":"key\n\t\t\t\t20171012073151_B10","unstructured":"Techniques of blood pressure measurement. In: CBO guideline High Blood Pressure. Alphen aan den Rijn: Van Zuiden Communications BV; 2000, 37\u201338."},{"key":"key\n\t\t\t\t20171012073151_B11","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macro vascular and micro vascular complications in type 2 diabetes: UKPDS 38. BMJ1998; 317:703\u2013713.","DOI":"10.1136\/bmj.317.7160.703"},{"key":"key\n\t\t\t\t20171012073151_B12","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macro vascular and micro vascular complications in type 2 diabetes: UKPDS 39. BMJ1998; 317:713\u2013720.","DOI":"10.1136\/bmj.317.7160.713"},{"key":"key\n\t\t\t\t20171012073151_B13","unstructured":"Rutten GEHM, Verhoeven S, Heine RJ et al. NHG-Standaard Diabetes Mellitus Type 2 (eerste herziening). (NHG Practice Guideline Diabetes Mellitus Type 2 (first revision)). Huisarts Wet1999; 42:67\u201384."},{"key":"key\n\t\t\t\t20171012073151_B14","unstructured":"Tholl U, Anlauf M, Lichtblau U, Dammer R. A clinical evaluation of the Omron R5-I (HEM-630) wrist blood pressure monitor and the Omron M5-I (HEM-757) upper arm blood pressure monitor, based on auscultation according to the \u2018g\u0171tesiegelprotocol\u2019. Germany: Academic Hospital of G\u0151ttingen University, Bremerhaven Hochscule. Unpublished Report 2003."},{"key":"key\n\t\t\t\t20171012073151_B15","doi-asserted-by":"crossref","unstructured":"El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit2003; 8:127\u2013133.","DOI":"10.1097\/00126097-200306000-00006"},{"key":"key\n\t\t\t\t20171012073151_B16","unstructured":"El Assaad M, Topouchian J, Le Dudal K, Labaki G, Asmar R. Validation of the Omron\u00ae M5-I blood pressure device according to the international validation protocol. J Hypertens2003; 21(Suppl. 4):S23."},{"key":"key\n\t\t\t\t20171012073151_B17","doi-asserted-by":"crossref","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet1986; 1:307\u2013310.","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"key\n\t\t\t\t20171012073151_B18","unstructured":"Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care2005; 11:206\u2013210."},{"key":"key\n\t\t\t\t20171012073151_B19","doi-asserted-by":"crossref","unstructured":"Sequeira RP, Al Khaja KA, Damanhori AH. Evaluating the treatment of hypertension in diabetes mellitus: a need for better control? J Eval Clin Pract2004; 10:107\u2013116.","DOI":"10.1111\/j.1365-2753.2003.00404.x"},{"key":"key\n\t\t\t\t20171012073151_B20","doi-asserted-by":"crossref","unstructured":"Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care2003; 26:355\u2013359.","DOI":"10.2337\/diacare.26.2.355"},{"key":"key\n\t\t\t\t20171012073151_B21","doi-asserted-by":"crossref","unstructured":"Schaars CF, Denig P, Kasje WN, Stewart RE, Wolffenbuttel BH, Haaijer-Ruskamp FM. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care2004; 27:123\u2013128.","DOI":"10.2337\/diacare.27.1.123"},{"key":"key\n\t\t\t\t20171012073151_B22","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998; 317:703\u2013713.","DOI":"10.1136\/bmj.317.7160.703"},{"key":"key\n\t\t\t\t20171012073151_B23","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ1998; 317:713\u2013720.","DOI":"10.1136\/bmj.317.7160.713"},{"key":"key\n\t\t\t\t20171012073151_B24","doi-asserted-by":"crossref","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA2002; 288:2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"},{"key":"key\n\t\t\t\t20171012073151_B25","doi-asserted-by":"crossref","unstructured":"Davis BR, Cutler JA, Gordon DJ et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Research Group. Am J Hypertens1996; 9:342\u2013360.","DOI":"10.1016\/0895-7061(96)00037-4"},{"key":"key\n\t\t\t\t20171012073151_B26","doi-asserted-by":"crossref","unstructured":"Dahlof B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens1997; 10:705\u2013713.","DOI":"10.1016\/S0895-7061(97)88956-X"},{"key":"key\n\t\t\t\t20171012073151_B27","doi-asserted-by":"crossref","unstructured":"Dahlof B, Devereux RB, Julius S et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention for endpoint reduction in hypertension. Hypertension1998; 32:989\u2013997.","DOI":"10.1161\/01.HYP.32.6.989"},{"key":"key\n\t\t\t\t20171012073151_B28","doi-asserted-by":"crossref","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359:995\u20131003.","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"key\n\t\t\t\t20171012073151_B29","doi-asserted-by":"crossref","unstructured":"Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet1998; 351:1755\u20131762.","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"key\n\t\t\t\t20171012073151_B30","doi-asserted-by":"crossref","unstructured":"Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int2003; 63:1499\u20131507.","DOI":"10.1046\/j.1523-1755.2003.00885.x"},{"key":"key\n\t\t\t\t20171012073151_B31","doi-asserted-by":"crossref","unstructured":"Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001; 345:861\u2013869.","DOI":"10.1056\/NEJMoa011161"},{"key":"key\n\t\t\t\t20171012073151_B32","doi-asserted-by":"crossref","unstructured":"Wing LM, Reid CM, Ryan P et al. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exp Hypertens1997; 19:779\u2013791.","DOI":"10.3109\/10641969709083186"},{"key":"key\n\t\t\t\t20171012073151_B33","doi-asserted-by":"crossref","unstructured":"Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting\u2014enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med2003; 348:583\u2013592.","DOI":"10.1056\/NEJMoa021716"},{"key":"key\n\t\t\t\t20171012073151_B34","unstructured":"The HOPE study investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol1996; 12:127\u2013137."},{"key":"key\n\t\t\t\t20171012073151_B35","doi-asserted-by":"crossref","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000; 342:145\u2013153.","DOI":"10.1056\/NEJM200001203420301"},{"key":"key\n\t\t\t\t20171012073151_B36","doi-asserted-by":"crossref","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001; 345:870\u2013878.","DOI":"10.1056\/NEJMoa011489"},{"key":"key\n\t\t\t\t20171012073151_B37","doi-asserted-by":"crossref","unstructured":"Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet1998; 352:1347\u20131351.","DOI":"10.1016\/S0140-6736(98)03086-4"},{"key":"key\n\t\t\t\t20171012073151_B38","doi-asserted-by":"crossref","unstructured":"Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med2002; 162:2046\u20132052.","DOI":"10.1001\/archinte.162.18.2046"},{"key":"key\n\t\t\t\t20171012073151_B39","doi-asserted-by":"crossref","unstructured":"Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet1997; 350:757\u2013764.","DOI":"10.1016\/S0140-6736(97)05381-6"},{"key":"key\n\t\t\t\t20171012073151_B40","doi-asserted-by":"crossref","unstructured":"SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic hypertension in the elderly program (SHEP). JAMA1991; 265:3255\u20133264.","DOI":"10.1001\/jama.265.24.3255"},{"key":"key\n\t\t\t\t20171012073151_B41","doi-asserted-by":"crossref","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001; 358:1033\u20131041.","DOI":"10.1016\/S0140-6736(01)06178-5"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/fampra\/article-pdf\/23\/1\/20\/1473398\/cmi096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T11:33:27Z","timestamp":1586604807000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/fampra\/article\/23\/1\/20\/554644\/Pitfalls-in-blood-pressure-measurement-in-daily"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,12,6]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmi096","relation":{},"ISSN":["1460-2229","0263-2136"],"issn-type":[{"value":"1460-2229","type":"electronic"},{"value":"0263-2136","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2]]},"published":{"date-parts":[[2005,12,6]]}}}